Rahman M, Zaki Ahmad M, Kazmi I, Akhter S, Afzal M, Gupta G, et al
A 5 to 8 minute plasma half-life means that by the time subcutaneously injected DSIP is absorbed from the injection site, cleared through lymphatics into venous blood, and circulated, a very substantial fraction has already been enzymatically degraded
The pre-blended format eliminates variability from separate reconstitution and simplifies protocols for researchers investigating multi-peptide approaches to recovery and repair
Common Mild Reactions Local irritation where the peptide was injected (minor redness or tenderness) Occasional dizziness or fatigue shortly after use Typically mild and short-lived Potential Risks Not FDA-approved for Lyme disease or any other condition Contraindicated in active cancer due to its angiogenesis-promoting properties Should be avoided during pregnancy or breastfeeding Take Precautions with Medical Guidance Since its administered via injection and isnt regulated for Lyme treatment, a professional Lyme disease expert should guide your dosing
KPV (LysProVal) A minimal anti-inflammatory tripeptide fragment of -melanocyte-stimulating hormone (-MSH), KPV acts primarily through MC1R-mediated and NF-Binhibitory pathways
